Heath Cotter
Family Medicine · Rifle, CONPI 1184819971
Payments from drug & device makers
Across 152 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$585
- AbbVie$341
- AstraZeneca$317
- Lilly USA, LLC$290
- Kerecis Limited$263
- GSK$210
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,364100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 16 | $585 |
| AbbVie(2 entities) | 21 | $341 |
| AstraZeneca | 17 | $317 |
| Lilly USA, LLC | 20 | $290 |
| Kerecis Limited | 3 | $263 |
| GSK | 11 | $210 |
| Pfizer | 11 | $180 |
| Reprise Biomedical, Inc. | 3 | $164 |
| Biohaven Pharmaceuticals, Inc. | 7 | $140 |
| Biowound Solutions, Inc. | 1 | $99 |
| Bard Peripheral Vascular, Inc. | 1 | $87 |
| Astellas Pharma US Inc | 4 | $79 |
| Amgen | 4 | $75 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Johnson & Johnson | 4 | $55 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Novo Nordisk | 2 | $32 |
| Novartis | 1 | $31 |
| Shockwave Medical, Inc | 1 | $25 |
| Mylan Specialty L.p. | 1 | $25 |
| Organogenesis Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Reddress USA, Inc. | 1 | $13 |
| Sobi, Inc | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,376 in reported general payments places this provider in the 90th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 133 | $169,962 |
| Taltz AutoinjectorIxekizumab | 17 | $121,889 |
| MounjaroTirzepatide | 80 | $92,752 |
| TrulicityDulaglutide | 75 | $85,151 |
| OzempicSemaglutide | 69 | $78,119 |
| EliquisApixaban | 55 | $61,857 |
| XareltoRivaroxaban | 19 | $26,124 |
| RybelsusSemaglutide | 16 | $24,970 |
| Emgality PenGalcanezumab-Gnlm | 21 | $23,006 |
| UbrelvyUbrogepant | 17 | $16,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,194 |
| NayzilamMidazolam | 14 | $10,903 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,223 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $8,032 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $7,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $290 | $179,386166 claims |
| Novo NordiskOzempic, Rybelsus | $32 | $103,08885 claims |
| PfizerEliquis | $180 | $61,85755 claims |
| Johnson & JohnsonXarelto | $55 | $26,12419 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $210 | $21,41734 claims |
| AbbVieUbrelvy | $341 | $16,97117 claims |
| UCB, Inc.Nayzilam | $16 | $10,90314 claims |
| MerckBelsomra | $14 | $6,34312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Rifle
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
- Astrid LampeyFraser$568K
- Kari UusinarkausWoodland Park$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.